SAB Biotherapeutics (SABS) Non Operating Income (2021 - 2025)
Historic Non Operating Income for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $58.1 million.
- SAB Biotherapeutics' Non Operating Income rose 595490.65% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.9 million, marking a year-over-year increase of 89759.86%. This contributed to the annual value of $8.8 million for FY2024, which is 31379.83% up from last year.
- According to the latest figures from Q3 2025, SAB Biotherapeutics' Non Operating Income is $58.1 million, which was up 595490.65% from -$382209.0 recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Non Operating Income registered a high of $58.1 million during Q3 2025, and its lowest value of -$4.0 million during Q4 2023.
- Its 5-year average for Non Operating Income is $4.1 million, with a median of $220605.0 in 2023.
- Per our database at Business Quant, SAB Biotherapeutics' Non Operating Income crashed by 3616802.5% in 2023 and then soared by 1310814.09% in 2024.
- SAB Biotherapeutics' Non Operating Income (Quarter) stood at -$450448.0 in 2021, then surged by 102.45% to $11043.0 in 2022, then crashed by 36168.02% to -$4.0 million in 2023, then soared by 65.21% to -$1.4 million in 2024, then surged by 4294.11% to $58.1 million in 2025.
- Its Non Operating Income was $58.1 million in Q3 2025, compared to -$382209.0 in Q2 2025 and $5.6 million in Q1 2025.